Exhibit 99.1

   Interleukin Genetics Announces Delay in Filing Annual Report on
            Form 10-K for the Year Ended December 31, 2004

    WALTHAM, Mass.--(BUSINESS WIRE)--April 1, 2005--Interleukin
Genetics, Inc. (OTCBB: ILGN) announced that it is conducting a review
of the accounting treatment of its March 2003 sale of Series A
Convertible Preferred Stock and convertible long-term debt in its
previously reported financial statements for the year ended December
31, 2003 and that the filing of its Annual Report on Form 10-K for the
year ended December 31, 2004 will be delayed until the completion of
the review. This review was occasioned by a reconsideration of the
Financial Accounting Standards Board's Emerging Issues Task Force
Issue No. 00-27, Application of EITF Issue No. 98-5, "Accounting for
Convertible Securities with Beneficial Conversion Features."

    About Interleukin

    Interleukin Genetics is a biotechnology company focused on
developing personalized health products. The company uses functional
genomics to help in the development of risk assessment tests,
pharmacogenetic tests, nutritional and therapeutic products based on
the genetic variations in people. Interleukin's current programs focus
on cardiovascular disease, osteoporosis, rheumatoid arthritis,
endometriosis, periodontal disease and weight management. Interleukin
expects that these programs will lead to products that will
personalize the selection of nutritional and therapeutic products and
enable the managed care industry to improve patient care and better
allocate resources. For more information about Interleukin and its
ongoing programs, please visit http://www.ilgenetics.com.

    Certain statements contained herein are "forward-looking"
statements including statements regarding the restatement of our
financial statements for the year ended December 31, 2003 and our
expectation that the restatement will not affect operating revenues or
expenses. Because such statements include risks and uncertainties,
actual results may differ materially from those expressed or implied
by such forward-looking statements. Factors that could cause actual
results to differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, the
results of our review of the accounting treatment of the March 2003
transactions and those risks and uncertainties described in our annual
report on Form 10-K, our quarterly reports on Form 10-Q and in other
filings made by us with the Securities and Exchange Commission. We
disclaim any obligation or intention to update these forward-looking
statements.

    CONTACT: For Interleukin Genetics:
             Fenel M. Eloi, 781-398-0700